REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Nov. 5, 2024-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced acceptance of an oral presentation at the upcoming American College of Rheumatology (ACR) Convergence 2024 meeting, taking place November 14-19, 2024, in Washington, D.C.

Details of the oral presentation are as follows:

Title: ADI-001: An Allogeneic CD20-targeted γδ CAR T Cell Therapy with Potential for Improved Tissue Homing in Autoimmune Indications
Session Name: Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases II
Abstract Number: 1866169
Presenting Author: Monica Moreno, Ph.D.
Date and Time: November 19, 2024; 12:00 p.m. – 12:15 p.m. ET

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241105685914/en/

Adicet Bio., Inc.
Investor and Media Contacts

Investors:
Anne Bowdidge
abowdidge@adicetbio.com

Janhavi Mohite
Precision AQ
212-362-1200
janhavi.mohite@precisionaq.com

Media:
Kerry Beth Daly
kbdaly@adicetbio.com

Source: Adicet Bio, Inc.